Premium
Antiallergic activity of topical lodoxamide on in vivo and in vitro models
Author(s) -
Ciprandi G.,
Buscaglia S.,
Catrullo A.,
Paolieri F.,
Riccio A. M.,
Fiorino N.,
Caica G. W.
Publication year - 1996
Publication title -
allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.363
H-Index - 173
eISSN - 1398-9995
pISSN - 0105-4538
DOI - 10.1111/j.1398-9995.1996.tb04499.x
Subject(s) - immunology , medicine , mast cell
Lodoxamide is an antiallergic drug acting as a mast‐cell stabilizer, which is effective in the treatment of allergic conjunctivitis. The study aimed to evaluate the effect of lodoxamide eye‐drops on the inflammatory early‐phase reaction (EPR) changes induced by allergen‐specific conjunctival challenge (ASCC). This was a cross‐over, double‐blind, placebo‐controlled, randomized study, including 10 outpatients suffering from allergic rhinoconjunctivitis due to Parietaria judaica . Patients received one drop of lodoxamide tromethamine 0.1% or placebo 30 min before each ASCC. Clinical evaluation and cytologic assessment were done at baseline and 30 min after each ASCC. Lodoxamide induced a reduction in total symptom score and hyperemia during the EPR ( P < 0.05). Lacrimation, itching/ burning, and eyelid swelling were only slightly (nonsignificantly) reduced. Lodoxamide induced a reduction in the total number of inflammatory cells and neutrophils during the EPR ( P < 0.02). Eosinophil and lymphocyte number and ICAM‐1 expression showed only a slight, not statistically significant decrease. Placebo did not affect the studied parameters. Lodoxamide reduced early clinical events and cellular changes after ASCC consistently with its activity as mast‐cell stabilizer. Moreover, lodoxamide was able to downregulate in vitro ICAM‐1 expression on the continuously cultured, differentiated conjunctival cell line WK. This was shown both in basal conditions ( P < 0.05) and upon interferon‐gamma stimulation ( P < 0.03), although at high concentration.